Octimet bags €11m for development of cancer drugs
Belgian start-up company Octimet Oncology NV has secured €11.3m in a series A financing round. The funds will be used to develop two MET kinase blockers to treat solid tumours.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Joint-venture Fibrocor tackles fibrosis
Drug screening expert Evotec AG and Ontario-based MaRS Innovation have launched the joint venture company Fibrocor Therapeutics LP to tackle fibrosis, an unmet medical need and multi-billion US dollars market.
New technology speeds up mapping of DNA-protein interaction
Scientists at EPFL have developed a technique that can be a game-changer for genetics by making the characterisation of DNA-binding proteins much faster, more accurate, and efficient.
Telix licenses Wilex girentuximab programme
German Wilex has licensed its clear cell renal cell carcinoma (ccRCC) antibody Redectane to Australian biopharma company Telix Pharmaceuticals. Redectane is a radiolabeled version of Wilex Phase III therapeutic antibody girentuximab.
EU neonicotinoid ban causes environmental damage
Severe economic and environmental damage: A study commissioned by EU industry association Euroseeds says that the ban of a certain class of insecticides to protect bees causes a lot of ecologic and economic burden.
Curevac reports another failed cancer vaccine
For thirty years, industry has worked hard to establish vaccines that can cure cancer. At the 35th JP Morgan Healthcare Conference, German Curevac reported another failure. It remains open whether cancer vaccines or co-administration of other drug classes to immune checkpoint modulators can break solid tumours immune tolerance tactics.
Researchers overcome chemotherapy resistance in AML
German researchers have found a biomarker that reliably predicts outcomes of blood cancer treatment with the chemotherapeutic cytarabine. Targeting the biomarker restored cytarabine sensitivity.
Caution returns to European biotech stocks
After the record-breaking year of 2015, biotech stock markets exercised more caution in 2016. However, according to a new report, this represents a healthy reset rather than a new crisis.
Roche gets FDA priority review for atezolizumab
Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.
UK researchers find metastasis switch in breast cancer cells
Constitutive activation of the mechano-sensor and transcription factor Yes-associated protein (YAP) is key to metastasis and epithelial-mesenchymal transition of triple-negative breast cancer, researchers from the Institute of Cancer Research, London, report.